Ipamorelin
Last reviewed 2026-10-30
Our read Opinion
Historical phase 2 research does not establish wellness efficacy. Its 503A nomination was withdrawn; acetate remains Category 2 under 503B, and WADA 2026 S2.2.4 prohibits it.
- Type
- Research-only / unapproved
- Regulatory status
- Not FDA-approved; no verified marketing authorization
- Compounding status
- Not cleared (advisory panel rejected)
- FDA-approved indications
- None
- Evidence level
- Small/early human studies
- Routes studied
- —
- WADA
- Prohibited
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to increase natural growth hormone release
- —Claimed to support fat loss, lean muscle, sleep quality and recovery
Ghrelin-receptor agonist that stimulates growth-hormone release and can affect gastrointestinal motility. Hormone release alone does not establish anti-aging benefit.
Not FDA-approved. Studied clinically for postoperative ileus, but no verified marketing authorization; FDA flags injectable safety uncertainties.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
Human study experience is not an endorsement for chronic wellness use. Regulatory assessments and incomplete safety data warrant caution.
No news yet for this peptide.
Bigger natural growth-hormone pulses for fat loss, lean muscle, sleep quality and recovery.
Lose fat on a GLP-1 while holding on to muscle.
Visceral (belly) fat reduction plus a broader GH boost.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.